Almasmoum H
Cancer Manag Res. 2021; 13:3271-3280.
PMID: 33883940
PMC: 8053700.
DOI: 10.2147/CMAR.S299089.
Shigematsu Y, Inamura K, Mise Y, Saiura A, Rehnberg E, Yamamoto N
Oncotarget. 2018; 9(24):17056-17065.
PMID: 29682204
PMC: 5908305.
DOI: 10.18632/oncotarget.24842.
Knowles K, Chen S, Herrera G
Am J Case Rep. 2017; 18:263-266.
PMID: 28289273
PMC: 5362023.
DOI: 10.12659/ajcr.901501.
Bae J, Lee T, Cho N, Kim T, Kang G
World J Gastroenterol. 2015; 21(5):1457-67.
PMID: 25663765
PMC: 4316088.
DOI: 10.3748/wjg.v21.i5.1457.
Kim J, Kang G
World J Gastroenterol. 2014; 20(15):4230-43.
PMID: 24764661
PMC: 3989959.
DOI: 10.3748/wjg.v20.i15.4230.
CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling.
Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C
J Clin Invest. 2012; 123(1):299-314.
PMID: 23202735
PMC: 3533294.
DOI: 10.1172/JCI64745.
CDX2 is an amplified lineage-survival oncogene in colorectal cancer.
Salari K, Spulak M, Cuff J, Forster A, Giacomini C, Huang S
Proc Natl Acad Sci U S A. 2012; 109(46):E3196-205.
PMID: 23112155
PMC: 3503165.
DOI: 10.1073/pnas.1206004109.
Differential colorectal carcinogenesis: Molecular basis and clinical relevance.
Moran A, Ortega P, De Juan C, Fernandez-Marcelo T, Frias C, Sanchez-Pernaute A
World J Gastrointest Oncol. 2010; 2(3):151-8.
PMID: 21160823
PMC: 2999176.
DOI: 10.4251/wjgo.v2.i3.151.
Polycomb group proteins: navigators of lineage pathways led astray in cancer.
Bracken A, Helin K
Nat Rev Cancer. 2009; 9(11):773-84.
PMID: 19851313
DOI: 10.1038/nrc2736.
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J
Clin Cancer Res. 2009; 15(14):4665-73.
PMID: 19584150
PMC: 2777758.
DOI: 10.1158/1078-0432.CCR-09-0401.
Linking the ovarian cancer transcriptome and immunome.
Rapberger R, Perco P, Sax C, Pangerl T, Siehs C, Pils D
BMC Syst Biol. 2008; 2:2.
PMID: 18173842
PMC: 2265674.
DOI: 10.1186/1752-0509-2-2.
The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis.
Scholl C, Bansal D, Dohner K, Eiwen K, Huntly B, Lee B
J Clin Invest. 2007; 117(4):1037-48.
PMID: 17347684
PMC: 1810574.
DOI: 10.1172/JCI30182.
Relationships between the expressions of CDX1 and CDX2 mRNA and clinicopathologic features in colorectal cancers.
Kim G, Lee D, Kim H, Cheong J, Seo S, Heo J
Korean J Intern Med. 2006; 20(4):317-24.
PMID: 16491830
PMC: 3891078.
DOI: 10.3904/kjim.2005.20.4.317.
The caudal homeodomain protein activates Drosophila E2F gene expression.
Hwang M, Kim Y, Choi N, Park J, Oh E, Kwon E
Nucleic Acids Res. 2002; 30(23):5029-35.
PMID: 12466526
PMC: 137955.
DOI: 10.1093/nar/gkf640.
Expression of CDX2 in normal and neoplastic human colon tissue and during differentiation of an in vitro model system.
Qualtrough D, Hinoi T, Fearon E, Paraskeva C
Gut. 2002; 51(2):184-90.
PMID: 12117877
PMC: 1773308.
DOI: 10.1136/gut.51.2.184.
Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon.
Hinoi T, Tani M, Lucas P, Caca K, Dunn R, Macri E
Am J Pathol. 2001; 159(6):2239-48.
PMID: 11733373
PMC: 1850596.
DOI: 10.1016/S0002-9440(10)63074-X.
Expression of the gut-enriched Krüppel-like factor (Krüppel-like factor 4) gene in the human colon cancer cell line RKO is dependent on CDX2.
Dang D, Mahatan C, Dang L, Agboola I, Yang V
Oncogene. 2001; 20(35):4884-90.
PMID: 11521200
PMC: 2268091.
DOI: 10.1038/sj.onc.1204645.
The homeobox gene CDX2 in colorectal carcinoma: a genetic analysis.
Sivagnanasundaram S, Islam I, Talbot I, Drummond F, Walters J, Edwards Y
Br J Cancer. 2001; 84(2):218-25.
PMID: 11161380
PMC: 2363702.
DOI: 10.1054/bjoc.2000.1544.
DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer.
Iino H, Simms L, Young J, Arnold J, Winship I, Webb S
Gut. 2000; 47(1):37-42.
PMID: 10861262
PMC: 1727981.
DOI: 10.1136/gut.47.1.37.
Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways.
Jass J, Biden K, Cummings M, Simms L, Walsh M, Schoch E
J Clin Pathol. 1999; 52(6):455-60.
PMID: 10562815
PMC: 501434.
DOI: 10.1136/jcp.52.6.455.